 |
|
Controversies and Misconceptions in Malaria Chemoprophylaxis for Travelers
Lin H. Chen, MD;
Mary E. Wilson, MD;
Patricia Schlagenhauf, PhD
JAMA. 2007;297(20):2251-2263.
Context Controversies in malaria prevention arise from the absence of data, conflicting data between different studies, conflicting recommendations, deviation of local practice from scientific data, and varying risk thresholds. Misconceptions about the seriousness of malaria, the tolerability of chemoprophylaxis drugs, and the efficacy and safety of repellents contribute to the controversies.
Objectives To compare several national guidelines on malaria chemoprophylaxis to identify variations in recommendations. We reviewed studies on tolerability of mefloquine with particular focus on its neuropsychiatric adverse effects and influence on performance. We also describe why most recommended chemoprophylactic regimens fail to prevent relapses of Plasmodium vivax malaria and review available options.
Evidence Acquisition We searched scientific publications in MEDLINE via PubMED for relevant articles with a cutoff date of December 2006 using the search terms malaria, chemoprophylaxis, travel, mefloquine, neuropsychiatric adverse events, tolerability, vivax malaria, and primaquine. Additional references were obtained from bibliographies of the selected articles. There were no language restrictions.
Evidence Synthesis Gaps and conflicts exist among current guidelines. Health authorities vary in the chemoprophylaxis drugs they recommend, the indications for continuous prophylaxis vs no prophylaxis, and the use of standby emergency treatment. Despite widespread reports on the adverse effects of mefloquine, controlled studies found that serious neuropsychiatric adverse events occur at rates comparable with or lower than other chemoprophylaxis drugs. Moreover, mefloquine does not appear to impair performance while driving, flying, or diving. Vivax malaria causes significant illness in travelers, but current first-line chemoprophylaxis agents do not prevent relapses of vivax malaria. Although not licensed in most countries as primary prophylaxis, primaquine effectively prevents relapses of vivax malaria.
Conclusions Prevention of malaria in travelers requires detailed knowledge of malaria epidemiology and host-vector-parasite interactions. Decisions are complicated by a lack of standardized recommendations, controversies, and misconceptions. Improved international consensus is indicated to minimize conflicting guidelines, clarify controversies, and promote adherence to preventive measures.
Author Affiliations: Mount Auburn Hospital, Cambridge (Drs Chen and Wilson) and Harvard Medical School (Drs Chen and Wilson) and Harvard School of Public Health (Dr Wilson), Boston, Mass, and University of Zürich, University of Zürich Center for Travel Medicine, Zürich, Switzerland (Dr Schlagenhauf).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Malaria Chemoprophylaxis: Strategies for Risk Groups
Schlagenhauf and Petersen
Clin. Microbiol. Rev. 2008;21:466-472.
ABSTRACT
| FULL TEXT
Preventing malaria in travellers
Lalloo and Hill
BMJ 2008;336:1362-1366.
FULL TEXT
Differential Effects of Quinoline Antimalarials on Endocytosis in Plasmodium falciparum
Roberts et al.
Antimicrob. Agents Chemother. 2008;52:1840-1842.
ABSTRACT
| FULL TEXT
Artesunate for the Treatment of Severe Falciparum Malaria
Rosenthal
NEJM 2008;358:1829-1836.
FULL TEXT
Neurologic Involvement in Falciparum Malaria
JWatch Neurology 2007;2007:3-3.
FULL TEXT
Malaria 2007--Progressing Research, Persisting Challenges
Zuccotti and DeAngelis
JAMA 2007;297:2285-2286.
FULL TEXT
|
